Kornimate/medical-research-clean huggingface dataset:
longitudinal oral microbiome sampling for be

Conditions: Barrett Esophagus

Summary: this is a longitudinal cohort study to assess the impact of repeated sampling of an oral microbiome signature for barrett's esophagus (be). potential participants will be identified through chart review of patients who have had an endoscopy in the past three years.

saliva collection is non-invasive and can be performed in clinical and non-clinical settings. as such, saliva testing is a highly attractive method for diagnosing and/or monitoring disease. the investigators previously showed that the bacterial make-up ("microbiome") of saliva is highly distinct in patients with and without barrett's esophagus (be), a precursor to esophageal cancer that normally can only be diagnosed by undergoing an upper endoscopy. while the microbiome of saliva is felt to be relatively stable over time, it is unclear whether a microbiome signature for barrett's esophagus is reproducible within individuals. also, repeated testing of saliva may improve the ability to diagnose barrett's esophagus.

Eligibility criteria:
inclusion criteria: * scheduled for an upper endoscopy or had upper endoscopy within past three years * eighteen years of age or older * capable of producing a saliva sample * able to give informed consent * for be patients only: endoscopic evidence of barrett's esophagus (at least 1 cm maximal be length; i.e. prague classification: any c, m≥1), and intestinal metaplasia present on esophageal biopsies exclusion criteria: * history of head and neck cancer or esophageal squamous cell or gastric cancer * history of esophageal or gastric surgery * scheduled to undergo colonoscopy on the day of initial saliva collection * scheduled only for endoscopic retrograde cholangiopancreatography (ercp) or endoscopy ultrasound (eus) without accompanying standard upper endoscopy on the day of initial saliva collection * for be patients only: history of prior endoscopic therapy for be except a history of prior endoscopic mucosal resection (emr) of focal lesions without subsequent ablative therapy is permitted

Keywords: saliva sampling oral microbiome
efficacy and safety of cariprazine in the treatment of adolescent participants (13 to 17 years of age) with schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.


Eligibility criteria:
inclusion criteria: * dsm-5 primary diagnosis of schizophrenia. * schizophrenia diagnosis confirmed by the k-sads-pl administered at screening (visit 1) by a trained clinician. * panss score ≥ 70 and a score of ≥ 4 (moderate) on 2 or more of the 5 items on the positive subscale of the panss (delusions, conceptual disorganization, hallucinatory behavior, grandiosity, suspiciousness/persecution), at screening (visit 1) and baseline (visit 2). * cgi-s scale score of ≥ 4 (moderately ill) at screening (visit 1) and baseline (visit 2). exclusion criteria: * current diagnosis of bipolar disorder, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder due to another medical condition * diagnosis of intellectual disability (iq \< 70). * participant has a history of meeting dsm-5 diagnosis for any substance-related disorder (except caffeine- and tobacco-related) within the 3 months before visit 1.
what are the determinants of explicit and implicit motor imagery ability in stroke patients?

Conditions: Stroke; Healthy

Summary: motor imagery (mi) might be described as a dynamic process in which an individual mentally stimulates an action without any overt movement. after stroke, motor imagery ability is impaired and also due to structure of mi, not every stroke patients is able to perform mi. therefore, the aim of the study is a) to compare both explicit and implicit motor imagery ability (mia) between patients with stroke and healthy subjects, b) to examine predictive effects of clinical characteristics for mia after stroke.


Eligibility criteria:
inclusion criteria: * being between the ages of 18-80, * having a unilateral stroke for the first time and 0-6 months since stroke onset * 24 points and above in mini mental state examination (mmdm) * not having a disease that may interfere with the study such as cardiac diseases, orthopedic conditions,etc. exclusion criteria: * multiple strokes * sever cognitive dysfunction (\<24 points in mmdm) * unilateral neglect * upper extremity pain that interferes with the study or aggravated with movement * visual problems, aphasia or another sequel that might limit the assessment
validation of compat-sf spanish translation

Conditions: Chronic Pancreatitis

Summary: prospective translation validation pilot study that will collect data from spanish-speaking cp patients seen at methodist dallas medical center (mdmc) beginning june 2024 through july 2027, in order to validate a spanish-translated compat-sf instrument.

prospective translation validation pilot study that will collect data from spanish-speaking cp patients seen at methodist dallas medical center (mdmc) beginning june 2024 through july 2027, in order to validate a spanish-translated compat-sf instrument.

Eligibility criteria:
inclusion criteria: * 18 years or older in age * have a definite cp diagnosis and a stable pain pattern with no new interventions or medications in the last three months * able to read and understand the study information in spanish * personally signed and dated icf indicating that the subject has been informed of all pertinent aspects of the study * subject is willing and able to comply with the scheduled questionnaires exclusion criteria: * subjects who do not meet the criteria in section 4.1
the effect of pressure ulcer education on the knowledge level of the relatives of the patients

Conditions: Healthy

Summary: the purpose of this randomized controlled trial, which included pretest and posttest, was to examine the effectiveness of pressure ulcer prevention and care education given to caregivers of patients treated in a palliative care clinic. the key questions it aims to answer are: * does the routine clinical training given in the palliative care clinic have an effect on the knowledge level of patients' relatives about pressure ulcers? * does the pressure ulcer education given to the relatives of patients treated in the palliative care clinic have an effect on the level of knowledge about pressure ulcers? participants will participate in an educational activity on pressure ulcers. researchers will compare whether pressure ulcer training given to palliative care patient relatives is effective compared to routine service training with lecture, question-answer and presentation method.

one-to-one interviews will be conducted with the relatives of the patients in the experimental and control groups, and the appropriate time frame for the clinical operation will be determined. participants will be informed about the study at the time determined jointly with the companions and at the appropriate place for the clinic. personal information form and pressure ulcer information test will be distributed and collected as a pre-test to the participants in the control group. the participants in the control group will not receive any educational intervention by the researcher until the day of discharge. this group will receive routine clinical training given only in the hospital. training of patients and their relatives in clinics continues with the principle of "do-watch-check". this is how nurses conduct their routine clinical training. the pressure ulcer information test will be distributed and collected as a post-test to the control group on the day of the patients' discharge. personal information form and pressure ulcer information test will be distributed and collected as a pre-test to the participants in the experimental group. in addition to the training given to the participants in the experimental group with the routine "do-watch-check" principle in the clinic, face-to-face pressure ulcer training will be given by the researchers on the day of discharge. the presentation about the pressure ulcer will be given by the researchers in two periods of 30 min + 30 minutes using lectures, case studies and question-answer techniques. opinions were received from three field experts regarding the validity of the training content of the pressure ulcer topic (cgi: 1.00). the pressure ulcer knowledge test will be redistributed and collected as a final test on the day of discharge after completion of training.

Eligibility criteria:
inclusion criteria: * those who agree to participate in the study * native turkish, * 18 years and over * able to read and write exclusion criteria: * who refused to participate in the study * native language is not turkish * illiterate

Keywords: pressure ulcer caregiver education palliative care
awareness, care and treatment in obesity management

Conditions: Metabolism and Nutrition Disorder; Obesity

Summary: this study aims to assess barriers that prevent obesity patients from receiving adequate care for their condition. the non-interventional study will be administered in the form of a 30-minute, cross-sectional, online survey to various respondents. there is no experimentation involved in the process of data collection, and each survey poses minimal human risk. the study will evaluate lifestyle habits and weight management strategies perceived and/or practiced by each of 3 stakeholders in obesity: patients (people with obesity), providers, and employers. a customized survey will be administered to each of the 3 stakeholders, and data will be analyzed based on respondents' answers.


Eligibility criteria:
inclusion criteria the following inclusion criteria will be imposed for hcps: * practice in canada * spends at least 70% of time in direct patient care * seen at least 100 patients in past month * seen at least 10 patients in past month needing weight management * in practice 2-35 years * not affiliated with pharmaceutical, market research (mr) or advertising firms * pcp - physician, rn / np / lpn, or pa, dietitians * pcp - specialty is fp, im, gp * obesity specialist - physician, rn / np / lpn, or pa * obesity specialist - specialty is fp, im, gp, endocrinology, bariatrics, or bariatric surgery * obesity specialist - currently practice as an obesity medicine or weight loss management specialist the following inclusion criteria will be imposed for pwos (people with obesity): * age at least 18 years * lives in canada * recruitment will target a nationally representative canada sample. demographic indicators will be monitored throughout recruitment. * current bmi 30 kg/sqm or greater, not extremely fit/body building * sub-category - maintaining weight loss: lost at least 10% of body weight in the past 3 years and has kept weight off for at least a year * sub-category - treatment seeking: has committed to a plan to lose weight, or has successfully lost weight (self-report) or has spoken to an hcp about weight loss plan in the last 6 months. the following inclusion criteria will be imposed for employers: * age at least 18 years * works in a canadian province * company offers health insurance * responsible for making or influencing decisions about health insurance or health and wellness programs * works in a company that has 20 or more employees * believes there is a weight issue (attitudinal agreement) * not affiliated with pharmaceutical, market research (mr) or advertising firms exclusion criteria any respondent who work works for a pharmaceutical, health insurance, research, or advertising company will be excluded; as there may be self-presentation effects that could alter the interview questions.
compassionate use of erwinase for pediatric patients with acute lymphoblastic leukemia or non hodgkins lymphoma

Conditions: Acute Lymphoblastic Leukemia; Non Hodgkins Lymphoma

Summary: this is a compassionate use protocol for patients with acute lymphoblastic leukemia (all) who have developed hypersensitivity or intolerance to e. coli l-asparaginase and/or peg-l-asparaginase.

primary objective to provide erwinase to patients with acute lymphoblastic leukemia (all) or non-hodgkins lymphoma who are intolerant or have developed hypersensitivity to e. coli asparaginase and/or peg-asparaginase. treatment plan erwinia l-asparaginase administration will be given according to the protocol or non-protocol treatment plan under which the patient is currently being treated. erwinase will be discontinued in any patient experiencing an allergic reaction or any grade 3 or higher adverse event believed to be attributable to this agent.

Eligibility criteria:
inclusion criteria: * patients on treatment for acute lymphoblastic leukemia or non-hodgkins lymphoma receiving all-type therapy who have developed hypersensitivity or intolerance to e. coli l-asparaginase or peg-l-asparaginase or both. * informed consent explained to and signed by parent/legal guardian, with emphasis that although approved for use in europe and canada, erwinase is not approved by the united states food and drug administration exclusion criteria: * documented history of severe hypersensitivity or intolerance to erwinase
prevalence and consequences of hyperlactemia following pancreatic surgery

Conditions: Pancreatic Cancer; Pancreatic Cyst; Chronic Pancreatitis

Summary: the goal of this observational study is to investigate the role of lactate elevation. the main aims are: * determine the frequency of lactate elevation following pancreatic surgery and its relationship to postoperative complications * investigate what patient and surgical related factors that are associated with postoperative lactate elevation this is a retrospective study based on existing medical data and will not affect the medical care of the studied patients.


Eligibility criteria:
inclusion criteria: * patients undergoing pancreatic surgery 2016-2018 exclusion criteria: * patients unable to undergo scheduled surgery * missing data in the postoperative period

Keywords: pancreatic surgery
effect of salt restriction on renin activation

Conditions: Hypertension

Summary: the present prospective, randomized, crossover study is designed to investigate the effect of salt consumption on blood pressure in hypertensive subjects. secondary objectives of the study are to evaluate the effect of salt consumption on blood pressure among the subjects who are hypertensive and obese and normal according to body mass index and to evaluate the effect of salt consumption on renin activity in hypertensive subjects.

the present study is carried out with the subjects who are chosen among the nursing home residents in i̇zmir. the subjects were randomized to 2 groups and while one of these groups had low salt diet (50mmol), the other group had normal salt diet (250mmol) for 3 weeks. subjects had normal salt diet in their daily routine life for the following 2 weeks. according to crossover nature of the study, the group that had normal salt diet at the first 3 weeks of study had low salt diet at the last 3 weeks of the study. the other group that had low salt diet had the normal salt diet at the last 3 week of the study. at the beginning of the study, information such as demographic, family story, medical story, diet habits, concomitant medication and physical measurements (height, weight and waist circumference) were received from the subjects. 24 hour blood pressure of the subjects is measured for four times, before the beginning of diet specific to their groups, at the end of the 3-week diet, before the beginning of the second diet and at the end of their second diet. the subjects were asked for collecting 24-h urine in the same days of blood pressure measurement. sodium, potassium, urea, creatinin and microalbumin measurements were measured in the collected urine. blood samples were collected for three times, at the end of the 3-week diet, before the beginning of the second diet and at the end of their second diet. plasma renin activity and aldosterone levels were measured in the blood samples collected. aldosterone level was measured in the 24-hour urine in mentioned days.

Eligibility criteria:
inclusion criteria: * subjects who are 50 years and older * subjects whose systolic blood pressure is ≥ 140 mmhg * subjects whose diastolic blood pressure is ≥ 90 mmhg * subjects who is normal weighted defined as body mass index \ 30 * subjects who have intellectual capacity to adapt diets and 24 hour urine collection * informed about the study and consented to include the study exclusion criteria: * known heart failure * known renal failure * known chronic liver disease * antihypertensive drug use * nonsteroidal anti inflammatory (nsai) drug use

Keywords: hypertension,plasma renin activity,salt consumption
vitamin d status and the adequacy of vitamin d intake in early preterm infants

Conditions: Hypovitaminosis D

Summary: vitamin d is an essential nutrient. deficiency of vitamin d is widespread. the prevalence of vitamin d deficiency in early preterm infants is unknown. the american academy of pediatrics recommends a daily intake of 400 iu in order to achieve a serum concentration of 20 ng/ml of vitamin d. this recommendation presumes exposure to sunlight, the best source of vitamin d. this study assesses vitamin d status at birth and during hospital stay in infants delivered delivered at earlier than or at 32 weeks gestation. we also assess the adequacy of intake relative to the target set by the american academy of pediatrics for children.

vitamin d is important for bone health. deficiency of vitamin d is widespread and is associated with a variety of diseases. preterm infants are susceptible osteopenia of prematurity (op). vitamin d deficiency may contribute to op. the american academy of pediatrics (aap) recommends a daily intake of 400 iu in order to achieve a serum concentration of 20 ng/ml of vitamin d. this recommendation presumes exposure to sunlight, the best source of vitamin d. whether this level of intake or target serum concentration are achieved in early preterm infants is unknown. we hypothesize that because early preterm infants are sequestered in the newborn intensive care units for an extended period of time, they will be deficient in vitamin d and that the current nutritional intake may not be adequate in meeting the aap recommendation. we assessed the concentration of serum 25-hydroxyvitamin-d in parturient mothers and in their newborns if they were less than 32 week gestation. we monitored vitamin d intake during hospitalization in the newborn intensive care unit and serum 25-hydroxyvitamin-d at discharge.

Eligibility criteria:
inclusion criteria: * all neonates delivered at or less than 32 weeks gestation were eligible. exclusion criteria: * infants with lethal congenital malformation * infants that were not expected to survive to discharge * infants delivered from multiple gestation
a potential novel marker for liver fibrosis in nash: the soluble secreted form of the human asialoglycoprotein receptor

Conditions: Liver Fibrosis

Summary: soluble secreted proteins that are expressed uniquely in specific organs and whose formation of secretion is regulated by disease states are excellent markers for the disease. this is because the disease can be diagnosed by simply measuring the levels of the secreted protein in serum. a soluble form of the asialoglycoprotein receptor could be a promising candidate for such marker in the case of liver fibrosis secondary to steatohepatitis for which the existing markers are not satisfactory. the human asialoglycoprotein receptor (asgpr) is expressed only in hepatocytes. the h2a alternatively spliced variant of the asgpr h2 subunit differs from h2b variant only by the presence of an extra pentapeptide. eghrg, in the exoplasmic domain next to the membrane-spanning segment. h2a is rapidly cleaved to a36 kda fragment, comprising the entire ectodomain, which is secreted. h2a does not participate in a membrane bound receptor complex with h1 as in the case for h2b and thus it is not a subunit of the receptor but a precursor for a soluble secreted form of the protein (sh2a). although h2a is a type ii transmembrane protein, signal peptidase is probably responsible for the cleavage to the soluble form. the objective in this research proposal is to study the association between the level of sh2a. in the serum and the severity of fibrosis in steatohepatitis in patients undergoing bariatric surgery due to morbid obesity. the existence of sh2a in normal human serum is at very constant levels. on the other hand the membrane asgpr (expressed exclusively in hepatocytes) is profoundly down - regulated in liver cancer and cirrhosis. the investigators will analyze the levels of sh2a in serum from patients with steatohepatitis in different stages of fibrosis and compare with healthy subjects. a possible early down-regulation of sh2a in fibrosis may prove to be a valuable diagnostic tool.


Eligibility criteria:
inclusion criteria: 1. signed informed consent. 2. patient candidate to bariatric surgery. exclusion criteria: 1. liver biopsy during the last 12 months. 2. the surgeon consider liver biopsy as a special dander in a specific patient.

Keywords: human asialoglycoprotein receptor (asgpr) hepatocytes bariatric surgery
repurposing riluzole for cancer-related cognitive impairment: a pilot trial

Conditions: Breast Cancer

Summary: this is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (bdnf) levels of breast cancer survivors with cancer related cognitive impairment.


Eligibility criteria:
inclusion criteria: * female and male patients diagnosed with breast cancer * past exposure to chemotherapy, radiotherapy, surgery and/or other breast cancer interventions. there is no minimum treatment time to be considered eligible. * washout of 30 days from investigational interventions is required if the patient was previously treated in a research study. there is no washout required from placebo investigational interventions. washout for conventional interventions is up to the discretion of the investigator, if the conventional intervention is not planned to be concurrently administered with riluzole/placebo. * ≥18 years of age * perceived by patient or investigator that cognitive function has worsened since cancer diagnosis and/or beginning of cancer treatment * able to provide informed consent. * literacy in english, chinese, korean, vietnamese, or spanish, to complete the questionnaires. * patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes. note: patients who have visual impairment or have degenerative conditions (e.g. parkinsons's disease, etc.) can still participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance. exclusion criteria: * presence of brain metastasis * unwilling to undergo neuropsychological assessments necessary for the study. * women who are breastfeeding, pregnant or are planning to get pregnant during the study period. women of child-bearing potential (wocbp) must have a negative pregnancy test at screening if there is suspicion of pregnancy. a. female patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy. * history of suspected hypersensitivity to riluzole or to any of its excipients. * patients taking or planned to take medications/substances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole. * hepatic impairment as indicated by: ast or alt ≥ 3x upper limit normal (uln) * have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.